What is SkinVision?
SkinVision operates a clinically validated mobile application designed for accurate and timely skin cancer detection. Leveraging advanced artificial intelligence in conjunction with dermatological oversight, the app provides users with personalized skin health advice and recommended health pathways. With a user base exceeding 3 million globally, SkinVision empowers individuals to proactively manage their skin health, particularly those at higher risk due to sun exposure. The platform serves as a crucial link between patients, healthcare providers, and insurers, aiming to optimize skin health outcomes and enhance the early detection of skin cancer.
How much funding has SkinVision raised?
SkinVision has raised a total of $11M across 2 funding rounds:
Unspecified
$3.4M
Unspecified
$7.6M
Unspecified (2015): $3.4M with participation from Personal Health Solutions Capital and LEO Pharma
Unspecified (2018): $7.6M led by PHS Fund and LEO Pharma
Key Investors in SkinVision
Personal Health Solutions Capital
Personal Health Solutions Capital is an investment firm focused on the emerging consumer health and well-being market, backing businesses that enable individuals to manage their health through science-based, technology-enabled solutions.
LEO Pharma
LEO Pharma is a multinational Danish pharmaceutical company with a specialization in dermatology, contributing significant industry expertise to its portfolio companies.
What's next for SkinVision?
The substantial enterprise-level backing and recent strategic investment position SkinVision for accelerated growth and market penetration. This capital infusion is likely to be directed towards enhancing its AI algorithms, expanding its user reach, and potentially forging new partnerships within the healthcare ecosystem. The company's focus on early detection and proactive skin health management aligns with global trends in preventative medicine and digital health solutions, suggesting a trajectory towards broader adoption and integration into standard dermatological care pathways. Future developments may include expanding service offerings and strengthening its position as a leader in AI-powered dermatological diagnostics.
See full SkinVision company page
